Recruiting

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

I4V-MC-JAHX - ClinicalTrials.gov - NCT03773965

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of juvenile idiopathic arthritis in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
How long will I be in the trial?
The study will last about 264 weeks and may include up to 24 visits.
Email
Recruiting

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

I4V-MC-JAHX - ClinicalTrials.gov - NCT03773965

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of juvenile idiopathic arthritis in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
How long will I be in the trial?
The study will last about 264 weeks and may include up to 24 visits.
Email

Key Requirements

Age :

1-18

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

1-18

Sex

All

Participants must

Participants must have completed a previous study of baricitinib for the treatment of JIA

Participants must have not developed an allergy to baricitinib

Participants must NOT

Participants must not have permanently stopped baricitinib in the prior study

Trial Summary

Conditions the trial is for

Systemic Juvenile Idiopathic Arthritis

What the trial is testing?

Baricitinib

Could I receive a Placebo?

no

Enrollment Goal

190

Trial Dates

April 2019 - December 2027

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

1-18

Sex

All

Participants must

Participants must have completed a previous study of baricitinib for the treatment of JIA

Participants must have not developed an allergy to baricitinib

Participants must NOT

Participants must not have permanently stopped baricitinib in the prior study

Trial Summary

Conditions the trial is for

Systemic Juvenile Idiopathic Arthritis

What the trial is testing?

Baricitinib

Could I receive a Placebo?

no

Enrollment Goal

190

Trial Dates

April 2019 - December 2027

Trial Phase

3

Not the right fit? Sign up to receive updates on new Systemic Juvenile Idiopathic Arthritis trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Systemic Juvenile Idiopathic Arthritis Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?